Details of the Drug

General Information of Drug (ID: DMP9HBO)

Drug Name
Sucralfate
Synonyms SUL; Ulcerlmin; Sucralfate, Chugai; Sucralfate, Scios Nova
Indication
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [1]
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski):
4		 Molecular Weight 1577.9
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 37
Hydrogen Bond Donor Count 20
Hydrogen Bond Acceptor Count 55
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 6 - 20 hours []
Chemical Identifiers
Formula
C12H54Al9O55S8
Canonical SMILES
C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])COS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al])OS(=O)(=O)O[Al].O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al]
InChI
InChI=1S/C12H22O35S8.9Al.20H2O/c13-48(14,15)37-1-4-6(43-51(22,23)24)8(45-53(28,29)30)9(46-54(31,32)33)11(40-4)42-12(3-39-50(19,20)21)10(47-55(34,35)36)7(44-52(25,26)27)5(41-12)2-38-49(16,17)18;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h4-11H,1-3H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)(H,25,26,27)(H,28,29,30)(H,31,32,33)(H,34,35,36);;;;;;;;;;20*1H2/q;;8*+1;;;;;;;;;;;;;;;;;;;;/p-8/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m1............................./s1
InChIKey
YZPQNHUVIVIUCT-JTJNLBSYSA-F
Cross-matching ID
PubChem CID
121494085
CAS Number
54182-58-0
DrugBank ID
DB00364
TTD ID
D06ULU
ACDINA ID
D00641
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor-2 (FGF2) TTGKIED FGF2_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acne vulgaris
ICD Disease Classification ED80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fibroblast growth factor-2 (FGF2) DTT FGF2 6.36E-03 0.05 0.3
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Sucralfate
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sarecycline DMLZNIQ Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Sarecycline . Acne vulgaris [ED80] [3]
Coadministration of a Drug Treating the Disease Different from Sucralfate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Promazine DMZAL7W Minor Decreased absorption of Sucralfate due to adsorption of Promazine. Appearance/behaviour symptom [MB23] [4]
Ofloxacin DM0VQN3 Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [5]
Ciprofloxacin XR DM2NLS9 Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [5]
Trovafloxacin DM6AN32 Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [5]
Sparfloxacin DMB4HCT Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [5]
Gemifloxacin DMHT34O Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [5]
Norfloxacin DMIZ6W2 Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [5]
ABT-492 DMJFD2I Moderate Decreased absorption of Sucralfate due to formation of complexes caused by ABT-492. Bacterial infection [1A00-1C4Z] [5]
Omadacycline DMR2J95 Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Omadacycline. Bacterial infection [1A00-1C4Z] [3]
Levofloxacin DMS60RB Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [5]
Minocycline DMVN5OH Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Minocycline. Bacterial infection [1A00-1C4Z] [3]
Lomefloxacin DMVRH9C Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [5]
Tetracycline DMZA017 Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Tetracycline. Bacterial infection [1A00-1C4Z] [3]
Risedronate DM5FLTY Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Risedronate. Bone paget disease [FB85] [6]
Alendronate DMY2KX9 Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Alendronate. Bone paget disease [FB85] [6]
Grepafloxacin DMGLX0T Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Grepafloxacin. Bronchitis [CA20] [5]
Sotalol DML60TN Minor Decreased absorption of Sucralfate due to formation of complexes caused by Sotalol. Cardiac arrhythmia [BC9Z] [7]
Chenodiol DMQ8JIK Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Chenodiol. Cholelithiasis [DC11] [8]
Doxercalciferol DM6FG1P Major Altered absorption of Sucralfate caused by Doxercalciferol. Chronic kidney disease [GB61] [9]
Mephenytoin DM5UGDK Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Mephenytoin. Epilepsy/seizure [8A61-8A6Z] [10]
Timolol DM3NXRU Minor Decreased absorption of Sucralfate due to formation of complexes caused by Timolol. Essential hypertension [BA00] [7]
Nadolol DMW6GVL Minor Decreased absorption of Sucralfate due to formation of complexes caused by Nadolol. Essential hypertension [BA00] [7]
Ketoconazole DMPZI3Q Minor Altered absorption of Sucralfate caused by Ketoconazole. Fungal infection [1F29-1F2F] [11]
Carteolol DMFMDOB Minor Decreased absorption of Sucralfate due to formation of complexes caused by Carteolol. Glaucoma [9C61] [7]
Carvedilol DMHTEAO Minor Decreased absorption of Sucralfate due to formation of complexes caused by Carvedilol. Heart failure [BD10-BD1Z] [7]
Furosemide DMMQ8ZG Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Furosemide. Heart failure [BD10-BD1Z] [9]
Digoxin DMQCTIH Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Digoxin. Heart failure [BD10-BD1Z] [10]
Digitoxin DMWVIGP Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Digitoxin. Heart failure [BD10-BD1Z] [10]
Isoniazid DM5JVS3 Minor Altered absorption of Sucralfate caused by Isoniazid. HIV-infected patients with tuberculosis [1B10-1B14] [12]
Dolutegravir DMCZGRE Major Decreased absorption of Sucralfate due to formation of complexes caused by Dolutegravir. Human immunodeficiency virus disease [1C60-1C62] [13]
Paricalcitol DMYBV3G Major Altered absorption of Sucralfate caused by Paricalcitol. Hyper-parathyroidism [5A51] [9]
Acebutolol DM0TI4U Minor Decreased absorption of Sucralfate due to formation of complexes caused by Acebutolol. Hypertension [BA00-BA04] [7]
Bisoprolol DM3UZ95 Minor Decreased absorption of Sucralfate due to formation of complexes caused by Bisoprolol. Hypertension [BA00-BA04] [7]
Penbutolol DM4ES8F Minor Decreased absorption of Sucralfate due to formation of complexes caused by Penbutolol. Hypertension [BA00-BA04] [7]
Nebivolol DM7F1PA Minor Decreased absorption of Sucralfate due to formation of complexes caused by Nebivolol. Hypertension [BA00-BA04] [7]
Pindolol DMD2NV7 Minor Decreased absorption of Sucralfate due to formation of complexes caused by Pindolol. Hypertension [BA00-BA04] [7]
Labetalol DMK8U72 Minor Decreased absorption of Sucralfate due to formation of complexes caused by Labetalol. Hypertension [BA00-BA04] [7]
Quinapril DMR8H31 Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Quinapril. Hypertension [BA00-BA04] [9]
Levothyroxine DMHN027 Minor Decreased absorption of Sucralfate due to formation of complexes caused by Levothyroxine. Hypo-thyroidism [5A00] [14]
Allopurinol DMLPAOB Moderate Altered absorption of Sucralfate caused by Allopurinol. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [15]
Baloxavir marboxil DM1UV7F Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Baloxavir marboxil. Influenza [1E30-1E32] [16]
Propiomazine DMKY8V1 Minor Decreased absorption of Sucralfate due to adsorption of Propiomazine. Insomnia [7A00-7A0Z] [4]
Ibandronate DM0QZBN Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Ibandronate. Low bone mass disorder [FB83] [17]
Propranolol DM79NTF Minor Decreased absorption of Sucralfate due to formation of complexes caused by Propranolol. Migraine [8A80] [7]
Exjade DMHPRWG Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Exjade. Mineral absorption/transport disorder [5C64] [18]
Prochlorperazine DM53SRA Minor Decreased absorption of Sucralfate due to adsorption of Prochlorperazine. Nausea/vomiting [MD90] [4]
Promethazine DM6I5GR Minor Decreased absorption of Sucralfate due to adsorption of Promethazine. Nausea/vomiting [MD90] [4]
Thiethylperazine DMU3IET Minor Decreased absorption of Sucralfate due to adsorption of Thiethylperazine. Nausea/vomiting [MD90] [4]
Diclofenac DMPIHLS Minor Altered absorption of Sucralfate caused by Diclofenac. Osteoarthritis [FA00-FA05] [19]
Naproxen DMZ5RGV Minor Decreased absorption of Sucralfate due to formation of complexes caused by Naproxen. Osteoarthritis [FA00-FA05] [20]
Diflunisal DM7EN8I Minor Altered absorption of Sucralfate caused by Diflunisal. Pain [MG30-MG3Z] [7]
Levomepromazine DMIKFEL Minor Decreased absorption of Sucralfate due to adsorption of Levomepromazine. Psychotic disorder [6A20-6A25] [4]
Fluphenazine DMIT8LX Minor Decreased absorption of Sucralfate due to adsorption of Fluphenazine. Psychotic disorder [6A20-6A25] [4]
Triflupromazine DMKFQJP Minor Decreased absorption of Sucralfate due to adsorption of Triflupromazine. Psychotic disorder [6A20-6A25] [4]
Gatifloxacin DMSL679 Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [5]
Penicillamine DM40EF6 Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Penicillamine. Rheumatoid arthritis [FA20] [21]
Mesoridazine DM2ZGAN Minor Decreased absorption of Sucralfate due to adsorption of Mesoridazine. Schizophrenia [6A20] [4]
Thioridazine DM35M8J Minor Decreased absorption of Sucralfate due to adsorption of Thioridazine. Schizophrenia [6A20] [4]
Perphenazine DMA4MRX Minor Decreased absorption of Sucralfate due to adsorption of Perphenazine. Schizophrenia [6A20] [4]
Chlorpromazine DMBGZI3 Minor Decreased absorption of Sucralfate due to adsorption of Chlorpromazine. Schizophrenia [6A20] [4]
Trifluoperazine DMKBYWI Minor Decreased absorption of Sucralfate due to adsorption of Trifluoperazine. Schizophrenia [6A20] [4]
Cholic acid DM7OKQV Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Cholic acid. Synthesis disorder [5C52-5C59] [22]
Deferiprone DMS2M7O Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Deferiprone. Thalassaemia [3A50] [15]
Cinoxacin DM4EWNS Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Cinoxacin. Urinary tract infection [GC08] [5]
Nalidixic acid DMRM0JV Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Nalidixic acid. Urinary tract infection [GC08] [23]
Enoxacin DMYTE6L Moderate Decreased absorption of Sucralfate due to formation of complexes caused by Enoxacin. Urinary tract infection [GC08] [5]
Methdilazine DMAUHQX Minor Decreased absorption of Sucralfate due to adsorption of Methdilazine. Vasomotor/allergic rhinitis [CA08] [4]
Trimeprazine DMEMV9D Minor Decreased absorption of Sucralfate due to adsorption of Trimeprazine. Vasomotor/allergic rhinitis [CA08] [4]
⏷ Show the Full List of 68 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
FD&C blue no. 1 E00263 19700 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sucralfate 1000 mg tablet 1000 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7055).
2 Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14.
3 Cerner Multum, Inc. "Canadian Product Information.".
4 Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):.
5 Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
6 Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC.
7 D'Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17. [PMID: 2886325]
8 Product Information. Chenodal (chenodeoxycholic acid). Manchester Pharmaceutical, Fort Collins, CO.
9 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
10 McCarthy DM "Sucralfate." N Engl J Med 325 (1991): 1017-25. [PMID: 1886624]
11 Carver PL, Berardi RR, Knapp MJ, Rider JM, Kauffman CA, Bradley SF, Atassi M "In vivo interaction of ketoconazole and sucralfate in healthy volunteers." Antimicrob Agents Chemother 38 (1994): 326-9. [PMID: 7910724]
12 Hava M, Hurwitz A "The relaxing effect of aluminum and lanthanum on rat and human gastric smooth muscle in vitro." Eur J Pharmacol 156 (1973): 156-61. [PMID: 4715218]
13 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
14 Havrankova J, Lahaie R "Levothyroxine binding by sucralfate." Ann Intern Med 117 (1992): 445-6. [PMID: 1503346]
15 Cerner Multum, Inc. "Australian Product Information.".
16 Product Information. Xofluza (baloxavir marboxil). Genentech, South San Francisco, CA.
17 Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54. [PMID: 8845456]
18 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
19 Pedrazzoli Junior J, Pierossi M de A, Muscara MN, Dias HF, da Silva CM, Mendes FD, de Nucci G "Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers." Br J Clin Pharmacol 43 (1997): 104-8. [PMID: 9056060]
20 Canadian Pharmacists Association.
21 Haagsma CJ "Clinically important drug interactions with disease-modifying antirheumatic drugs." Drugs Aging 13 (1998): 281-9. [PMID: 9805209]
22 Product Information. Cholbam (cholic acid). Manchester Pharmaceutical, Fort Collins, CO.
23 Product Information. NegGram (nalidixic acid). Sanofi Winthrop Pharmaceuticals, New York, NY.